Hosted on MSN16d
After Plunging -13.71% in 4 Weeks, Here's Why the Trend Might Reverse for Aligos Therapeutics (ALGS)A downtrend has been apparent in Aligos Therapeutics, Inc. (ALGS) lately with too much selling pressure. The stock has ...
Title: Non-HAP CAM-A ALG-006746 and ALG-006780 induce rapid HBsAg reductions in AAV-HBV mice and have favorable pharmacokinetic profiles Presenter: Yannick Debing, PhD Abstracts identified as “Top” ...
Aligos Therapeutics Inc. and Katholieke Universiteit Leuven (KU Leuven ) have jointly developed new 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be ...
Topline data now projected in early Q4 2024 Rohit Loomba, MD, MHSc to serve as Principal Investigator SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ...
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Aligos Therapeutics (ALGS – Research Report) today and set a price target ...
Altimmune, Inc. is a biotech company exploring the potential of pemvidutide, a promising GLP-1 agonist. Click here for my ALT ...
Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback